Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domagrozumab in LGMD2I
NCT02841267Phase 2Completed
- Start
- Jul 2016
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of domagrozumab in limb-girdle muscular dystrophy type 2I (LGMD2I) (3 arms). Primary endpoint: Incidence of Dose Limiting or Intolerability Treatment Related Adverse Events at 64 weeks. Started Jul 2016; status: completed.
02
Drugs
domagrozumab
03
Conditions
limb-girdle muscular dystrophy type 2I (LGMD2I)
Beyond the preview
Go deeper on NCT02841267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02841267.